The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Garassino, Marina Chiara
One or more keywords matched the following items that are connected to Garassino, Marina Chiara
Item TypeName
Academic Article Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Academic Article Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Academic Article Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Academic Article Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Academic Article Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Academic Article Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Academic Article Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Academic Article Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
Academic Article Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Academic Article Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Academic Article Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Academic Article Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Academic Article Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
Academic Article Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Academic Article Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Academic Article Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab.
Academic Article Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors.
Academic Article Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Concept Antineoplastic Agents, Immunological
Academic Article High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Search Criteria
  • Antineoplastic Agents Immunological